318 related articles for article (PubMed ID: 10481111)
1. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
2. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
3. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
4. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
5. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
7. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
9. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.
Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K
Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258
[TBL] [Abstract][Full Text] [Related]
12. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
[TBL] [Abstract][Full Text] [Related]
13. The importance of monitoring colorectal adenomas by tumor markers (ROC analysis).
Stajic S; Novaković R; Kostić N; Josifovski J; Simić P; Katić V; Kovijanić M
Med Pregl; 1993; 46 Suppl 1():69-71. PubMed ID: 8569613
[TBL] [Abstract][Full Text] [Related]
14. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
Forones NM; Tanaka M
Hepatogastroenterology; 1999; 46(26):905-8. PubMed ID: 10370636
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
von Kleist S; Hesse Y; Kananeeh H
Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564
[TBL] [Abstract][Full Text] [Related]
16. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
17. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
19. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]